Clinical Trials Browser

OTHER × Carcinoma × Nivolumab × Clear all

NCT07430202 2026-02-24

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Phase 1 Not yet recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT06941857 2025-12-03

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Pancreatic Neoplasms

NCT05347212 2025-10-10

Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

Phase 2 Active not recruiting

Carcinoma

NCT03190265 2024-08-07

Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

Phase 2 Completed

61 enrolled 11 charts

Gastrointestinal

Adenocarcinoma, Carcinoma, Neoplasms, Pancreatic Neoplasms